European Union: Competition Law and Intellectual Property Go Another Round

Last Updated: 6 July 2010

Article by Gillian Sproul , Nathalie Jalabert-Doury , Kiran S. Desai and Jens Peter Schmidt

Originally published 2 July 2010

Keywords: competition law, intellectual property rights, AstraZeneca, abuse of market dominance, Losec, patent, EU Treaty, misleading representations,

In a new judgment that further explores the application of competition law to intellectual property rights, the EU General Court has upheld a 2005 Commission decision finding that AstraZeneca1 abused a market-dominant position by blocking or delaying the entry of generic versions of its ulcer drug Losec2. However, the Court has also reduced to €52.5 million the €60 million fine originally imposed on AstraZeneca, reflecting the Commission's failure to prove one element of its case.


The Court endorsed the Commission's finding that the product market relevant to Losec was the market for proton pump inhibitors ("PPIs"), since these were substantially superior to other products with the same therapeutic use. Losec's very high share of the market for PPIs gave AstraZeneca a dominant market position in the territories in which it engaged in the conduct challenged by the Commission.

The Abuse

The Court's decision establishes that conduct relating to patent applications and extensions, and to marketing procedures, may constitute an abuse of market dominance, within the meaning of Article 102 of the Treaty on the Functioning of the European Union ("TFEU"), where that conduct blocks or delays competitors' market entry.

The conduct at the centre of the case involved:

  • a pattern of misleading representations made by AstraZeneca to patent attorneys, national patent offices and national courts in a number of Member States with a view to gaining extended patent protection for omeprazole, the active substance in Losec, through supplementary protection certificates ("SPCs")3 and
    • a marketing strategy combining three elements:
    • selective requests by AstraZeneca for deregistration of market authorizations for Losec capsules in Denmark, Norway and Sweden,
    • withdrawal by AstraZeneca of Losec capsules from those markets and
    • the launch by AstraZeneca of Losec multiple unit pellet system ("MUPS") tablets.

The Appeal

AstraZeneca appealed on the basis that it had not intentionally provided misleading information in order to obtain SPCs for Losec; and that the introduction of a new Losec formulation and the withdrawal of Losec capsules amounted to a legitimate commercial policy designed to protect AstraZeneca's business from competition from generic producers and parallel importers.

The General Court's Judgment of 1 July 2010


The Court found that AstraZeneca did in fact make misleading representations in order to obtain SPCs to which it was not entitled. This type of conduct was not in keeping with the special responsibility of a dominant company not to impair genuine undistorted competition. It amounted to conduct that did not constitute competition on the merits.

AstraZeneca had argued that the existence of a fraudulent intention to cause harm to competition could not amount to an abuse of market dominance, but should be dealt with by the patent authorities under the relevant patent rules. It further argued that the competition authorities had Article 102 jurisdiction only over the enforcement (or threatened enforcement) of a fraudulently obtained patent or SPC. The Court disagreed: " ...the submission to the patent offices of objectively misleading representations by an undertaking in a dominant position which are of such a nature as to lead those offices to grant it SPCs to which it is not entitled or to which it is entitled for a shorter period, thus resulting in a restriction or elimination of competition, constituted an abuse of that position".

AstraZeneca's conduct had had an effect on competition from the time the SPCs were granted, despite the fact that they had not been enforced – their existence had kept competitors away. Further, the existence of a specific remedy for fraudulent representations in the patent system did not preclude the application of competition law.


The Court confirmed that the launch of Losec MUPS and the withdrawal of Losec capsules from the market did not in themselves constitute an abuse – they were not capable on their own of blocking competition from generic products and parallel imports. However, when these activities were combined with the deregistration of marketing authorisations for Losec capsules, they were capable of having these effects. In addition, the deregistrations had not been motivated by a legitimate need to protect AstraZeneca's investment, since it no longer had the exclusive right to exploit the results of its pharmacological tests and clinical trials. They were also not necessary to enable AstraZeneca to launch Losec MUPS.

Reduction in Penalty

Although the Court upheld the substance of the Commission's decision, it reduced AstraZeneca's fine by €7.5 million to €52.5 million. It found that the Commission had failed to prove that deregistrations of marketing authorisations for the Losec capsule in Denmark and Norway were specifically capable of restricting parallel imports.

What Happens Next?

This is the first time that the EU courts have had the opportunity to apply Article 102 TFEU to the way in which a dominant pharmaceutical company protects and uses its intellectual property rights ("IPRs"). It remains to be seen whether the judgment will stand unchallenged – judgments of the General Court may be appealed to the Court of Justice, on limited points of law only, within two months from the judgment date, so AstraZeneca has until 1 September to appeal.

Implications of the Judgment

In the meantime, the Court's judgment highlights the need for dominant firms to take particular care not to mislead when applying for patents, patent extensions or SPCs. The judgment blurs the traditional competition law distinction between the existence of IPR (not an abuse) and the exercise (or enforcement) of IPR (potentially an abuse) – in this context, it is clear that simply holding IPR will create liability under Article 102. Even a genuine error in information provided for the purpose of obtaining could constitute an abuse, although liability is likely to be reduced significantly if, on discovering the error, the company in question informs the patent authorities so that irregularities can be rectified. In addition, activities that in isolation are lawful may, when combined with other activities, result in liability, if their impact is to exclude competition from generics or parallel imports.


1. AstraZeneca AB and AstraZeneca Plc

2. Case T-321/05, Judgment of 1 July 2010; Action brought on 25 August 2005 — AstraZeneca/Commission, OJ 2005/C 271/47 – against Commission Decision of 15 June 2005, relating to a proceeding under Article 82 of the EC Treaty and Article 54 of the EEA Agreement (Case COMP/A. 37.507/F3 AstraZeneca) [2006] OJ L322/24.

3. SPCs are granted according to the provisions of Council Regulation 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products (OJ L 182). SPCs grant longer patent protection to pharmaceutical products, not exceeding five years after the expiration of the patent. SPCs were introduced to take into account of the lapse of time between patent registration and market authorization.

Learn more about our Antitrust & Competition, Intellectual Property and Life Sciences practices.

Visit us at

Mayer Brown is a global legal services organization comprising legal practices that are separate entities ("Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP, a limited liability partnership established in the United States; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales; and JSM, a Hong Kong partnership, and its associated entities in Asia. The Mayer Brown Practices are known as Mayer Brown JSM in Asia.

This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

Copyright 2010. Mayer Brown LLP, Mayer Brown International LLP, and/or JSM. All rights reserved.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions